IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,020 shares of the company’s stock after buying an additional 212 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in IDEXX Laboratories were worth $4,052,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Vicus Capital purchased a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $210,000. Aviance Capital Partners LLC purchased a new position in shares of IDEXX Laboratories during the first quarter worth $405,000. Oak Thistle LLC acquired a new stake in shares of IDEXX Laboratories in the first quarter valued at $297,000. Allspring Global Investments Holdings LLC raised its holdings in shares of IDEXX Laboratories by 10.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 40,771 shares of the company’s stock valued at $22,013,000 after buying an additional 3,886 shares during the period. Finally, Nvest Financial LLC lifted its stake in IDEXX Laboratories by 17.1% during the 1st quarter. Nvest Financial LLC now owns 1,882 shares of the company’s stock worth $1,016,000 after acquiring an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $451.41 on Friday. The firm has a market capitalization of $37.16 billion, a price-to-earnings ratio of 44.69, a PEG ratio of 4.03 and a beta of 1.33. The firm’s fifty day simple moving average is $484.62 and its 200-day simple moving average is $489.32. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.67 earnings per share. Equities analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research reports. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. BTIG Research initiated coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target for the company. Finally, Piper Sandler cut their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $574.13.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.